These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31734097)

  • 1. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    Shiha G; Soliman R; Mikhail NNH; Easterbrook P
    J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.
    Shiha G; Metwally AM; Soliman R; Elbasiony M; Mikhail NNH; Easterbrook P
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):778-789. PubMed ID: 30030068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.
    Shiha G; Soliman R; Mikhail NNH; Easterbrook P
    J Hepatol; 2021 Feb; 74(2):303-311. PubMed ID: 32931878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
    Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
    Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic overview of hepatitis C infection in the Middle East and North Africa.
    Chaabna K; Cheema S; Abraham A; Alrouh H; Lowenfels AB; Maisonneuve P; Mamtani R
    World J Gastroenterol; 2018 Jul; 24(27):3038-3054. PubMed ID: 30038471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness.
    Rajkumar N; Khumukcham LS; Thangjam D; Singh S; Khwairakpam G; Shilton S; Goel A
    Harm Reduct J; 2024 May; 21(1):98. PubMed ID: 38769517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt.
    Mostafa A; Shimakawa Y; Medhat A; Mikhail NN; Chesnais CB; Arafa N; Bakr I; El Hoseiny M; El-Daly M; Esmat G; Abdel-Hamid M; Mohamed MK; Fontanet A
    J Hepatol; 2016 Jun; 64(6):1240-6. PubMed ID: 26921686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    Ayoub HH; Abu-Raddad LJ
    J Viral Hepat; 2017 Jun; 24(6):486-495. PubMed ID: 28039923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal.
    Lin YC; Chiu WN; Chang TS; Huang TJ; Chen MY
    J Nurs Scholarsh; 2020 Mar; 52(2):128-135. PubMed ID: 31750620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
    Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
    Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
    Schwarz C; Bauer D; Dorn L; Jachs M; Hartl L; Chromy D; Weseslindtner L; Pfisterer N; Hennlich B; Stückler A; Strassl R; Voill-Glaninger A; Hübl W; Willheim M; Köhrer K; Jansen-Skoupy S; Tomez S; Krugluger W; Madl C; Schwarz M; Balcar L; Semmler G; Brinkmann L; Burghart L; Antonitsch L; Weidinger G; Riedl F; Laferl H; Kurteva V; Traugott M; Hind J; Wenisch C; Aburaia A; Sebesta C; Schmid D; Rothweiler S; Remetic J; Gschwantler M; Maieron A; Reiberger T
    Wien Klin Wochenschr; 2024 May; 136(9-10):278-288. PubMed ID: 37773541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.
    Abd Elrazek AE; Bilasy SE; Elbanna AEM; Elsherif AEA
    Medicine (Baltimore); 2014 Dec; 93(28):e204. PubMed ID: 25526438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of Hepatitis C virus infection in the Upper East Region of Ghana; a community-based cross-sectional study.
    Siaw ADJ; Amugsi J; Owusu-Konadu MAA; Drah ST; Imbeah EG; Oduro-Donkor D; Duah A; Nartey YA
    PLoS One; 2024; 19(6):e0306292. PubMed ID: 38941280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.